Journal
/
/
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Journal JoVE
Bio-ingénierie
Un abonnement à JoVE est nécessaire pour voir ce contenu.  Connectez-vous ou commencez votre essai gratuit.
Journal JoVE Bio-ingénierie
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
DOI:

14:03 min

March 24, 2023

, , , ,

Chapitres

  • 00:04Introduction
  • 00:57Commercially Available Cryopreserved hiPSC‐CMs Plating for Maturation on a Maturation‐Inducing Extracellular Matrix (MECM)
  • 03:02Human‐Induced Pluripotent Stem Cell‐Derived Cardiomyocytes (hiPSC‐CM) Purification
  • 06:01Optical Mapping Using Voltage‐Sensitive Dyes (VSDs) and Calcium‐Sensitive Fluorophores (CSFs)
  • 07:32Optical Mapping Using Genetically Encoded Calcium Indicator (GECI)
  • 08:18Acquisition of Optical Mapping Data and Analysis
  • 10:45Results: Robust and Rapid Maturation of Human Induced Pluripotent Stem Cell‐Derived Cardiomyocytes (hiPSC‐CMs)
  • 13:12Conclusion

Summary

Traduction automatique

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer an alternative to using animals for preclinical cardiotoxicity screening. A limitation to the widespread adoption of hiPSC-CMs in preclinical toxicity screening is the immature, fetal-like phenotype of the cells. Presented here are protocols for robust and rapid maturation of hiPSC-CMs.

Vidéos Connexes

Read Article